2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
Company Announcements

2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk

2seventy bio (TSVT) has shared an announcement.

2seventy bio, Inc. has entered into a lucrative deal with Novo Nordisk A/S, selling its gene therapy research program for an upfront $38 million in cash and the potential for an additional $2 million. This program focuses on the treatment and prevention of hemophilia. Novo Nordisk will take on certain liabilities and both companies have agreed to indemnify each other against certain losses. This strategic move will likely stir interest among stock market enthusiasts as 2seventy bio reshapes its portfolio and Novo Nordisk expands its healthcare offerings.

See more insights into TSVT stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated Newsdesk2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
TheFly2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma
TheFly2seventy Bio sees Q3 Abecma U.S. revenue growth ~ 30% vs. Q2
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App